Perrigo Company plc

NYSE:PRGO

Drug Manufacturers - Specialty & Generic

Healthcare
$16.94 -1.97%

-$0.20 today

Market cap
$2.35B
Beta
0.52
P/E (TTM)
-0.8
EPS (TTM)
-$13.10
Dividend yield
11.65%
52W Low $9.23High $28.44

Volume 2.57M

Average 2.96M

PRGO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Perrigo Company plcNYSE: PRGO

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $23.7M rose 7.7% year over year, ahead of the -7.3% change in trailing-twelve-month research & development. Sequentially, it fell 3.7% from the prior quarter. Over 3 fiscal years it compounded at -8.1% a year.

Context

  • Research & development amounted to 2.2% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +7.7% holds above the trailing-twelve-month pace of -7.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$23.7M-3.7% QoQ
Last fiscal yearDec 2025
$95.4M-15.0% YoY
LTMJun 2026
$95M-7.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.7%——
1 year-15.0%——
3-year CAGR-8.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
95.4M USD
Year-over-year change
-15.0%
4-year CAGR
-6.0%

Research & Development vs competitors

How PRGO compares with its peers on the latest reported figures

  • PRGO's LTM Jun 2026 research & development of $95M is the 8th highest of the 10 companies compared; the peer median is $126.09M.
  • Its year-over-year change of -7.3% is the 8th highest of 9, against a peer median of +7.9%.
  • Research & development amounts to 2.3% of revenue for PRGO, versus a peer median of 15.2%.
PRGO Competitors Peer median
Research & Development for PRGO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BHCBausch Health Companies Inc.LTM Jun 2026$634M +1.3%+5.9%5.8%
SRRKScholar Rock Holding CorporationLTM Sep 2026$211.05M -0.0%+18.8%37026.5%
LIVNLivaNova PLCLTM Sep 2026$202.57M +14.5%+6.0%13.4%
HCMHUTCHMED (China) LimitedLTM Jun 2025$190.1M -25.1%-15.0%31.6%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$126.09M +18.1%+12.5%15.2%
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026$115.59M +83.0%+14.7%16.9%
HTFLHeartflow, Inc. Common StockLTM Sep 2026$96.03M +64.1%—40.2%
PRGOPerrigo Company plcLTM Jun 2026$95M -7.3%-8.1%2.3%
ATECAlphatec Holdings, Inc.LTM Mar 2026$77.25M -2.6%+20.1%9.8%
SGRYSurgery Partners, Inc.LTM Sep 2026$0 ——0.0%
Peer median (excluding PRGO) $126.09M+7.9%+12.5%15.2%

Competitors are the stored peer set for PRGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.14B4.45B4.66B4.37B4.25B
Cost of Revenue2.72B3B2.98B2.83B2.76B
Gross Profit1.42B1.46B1.68B1.54B1.49B
Gross Margin34.2%32.7%36.1%35.3%35.1%
Research & Development122M123.1M122.5M112.2M95.4M
Selling, General & Admin1.11B1.21B1.27B1.11B526.5M
Operating Expenses1.01B1.38B1.53B1.43B1.15B
Depreciation & Amortization312.2M338.6M359.5M325.9M337.5M
EBITDA695.9M355.5M525M433M(797.9M)
EBITDA Margin16.8%8.0%11.3%9.9%-18.8%
Operating Income410.4M78.9M151.9M112.9M343.3M
Operating Margin9.9%1.8%3.3%2.6%8.1%
Interest Income00000
Interest Expense125M156M173.8M187.8M162.5M
Other Income / Expenses(151.7M)(218M)(160.2M)(193.6M)(1.64B)
Income Before Tax258.7M(139.1M)(8.3M)(80.7M)(1.3B)
Pre-Tax Margin6.3%-3.1%-0.2%-1.8%-30.5%
Income Tax Expense389.6M(8.2M)(3.9M)80M104.4M
Net Income(68.9M)(140.6M)(12.7M)(171.8M)(1.43B)
Net Margin-1.7%-3.2%-0.3%-3.9%-33.5%
EPS (Basic)(0.98)(0.97)(0.09)(1.25)(10.29)
EPS (Diluted)(0.98)(0.97)(0.09)(1.25)(10.29)
Weighted Avg Shares133.6M134.5M135.3M137.4M138.5M
Weighted Avg Shares (Diluted)133.6M134.5M135.3M137.4M138.5M

Perrigo Company plc

NYSE:PRGO

Intrinsic Alpha fair value

Locked

Current Price

$16.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.